诺华 NVS 深 沪
交易中 01-28 10:47:44 美东时间
148.30
-3.920
-2.58%
华盛通- 最 高149.38
- 今 开148.82
- 成交量 40.60万股
- 最 低 148.06
- 昨 收 152.22
- 总市值 2845.88亿
- 52周最高 152.48
- 市盈率 静 25.29
- 换手率 0.00%
- 52周最低 97.715
- 委 比 99.80%
- 总股本 19.19亿
- 历史最高 152.48
- 量 比 1.26
- 振 幅 0.87%
- 历史最低 6.9614
- 每 手 1
- 风险率 11.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
今天 18:51
美股盘后 | 诺华涨4.32%
诺华受仿制药竞争影响，Kesimpta产品库存去化或影响业绩，Mare Evidence Lab将其评级下调至"中性"，认为2026年为过渡期，目前股价已达目标价格，定价合理。
今天 05:02
SA analyst upgrades/downgrades: GM, UBER, UNH, NVS
In the auto industry, General Motors (GM) and Uber Technologies (UBER) have both received upgrades, with Seeking Alpha analysts citing improving margin dynamics and attractive risk/reward profiles. Me...
01-27 02:18
FOCUS-Drugmakers turn to AI to speed trials, regulatory submissions
FOCUS-Drugmakers turn to AI to speed trials, regulatory submissions Pharmaceutical companies describe AI benefits for tedious work Novartis says AI cut trial site selection from weeks to a two-hour meeting Drugmakers use AI to draft regulator-ready filings By Maggie Fick and Michael Erman SAN FRANCI
01-26 19:00
“CEO试图摇醒欧洲：把自己捯饬好，不然就等着输给中美吧”
【文/观察者网 王一】1月19日至23日在瑞士达沃斯举行的世界经济论坛，吸引了来自全球各行各业的800多名企业高管参加。据美国彭博社24日报道，从生物制药、人工...
01-24 11:59
出席达沃斯论坛的企业领袖告诫欧洲：不重整旗鼓 就会出局
无论是在制药、人工智能还是国防领域，本周出席达沃斯世界经济论坛的企业高管向欧洲发出了一个严厉警告：要么把内部事务理顺，否则就会在竞争中出局。 这些高管指...
01-24 01:33
Novartis Positions US Strategy As Defense Against Rising Trade Levies
Novartis CEO says US manufacturing investments and a federal agreement could limit tariff exposure as proposed Trump levies target Europe.
01-23 23:57
直击达沃斯丨医渡科技(02158)、文莱卫生部、诺华基金会宣布启动AI驱动的国家级心血管疾病防控项目
2026年世界经济论坛年会（冬季达沃斯论坛）上，诺华公司董事会主席Giovanni Caforio博士宣布一项重要合作：诺华基金会、文莱卫生部、医渡科技(02...
01-23 17:30
UPDATE 2-India's Cipla posts steeper-than-expected quarterly profit slump on tumour drug supply crunch
UPDATE 2-India's Cipla posts steeper-than-expected quarterly profit slump on tumour drug supply crunch Rewrites first paragraph, updates share movement in paragraph 2, adds details throughout Jan 23 (Reuters) - Cipla CIPL.NS , India's third-largest drugmaker by revenue, reported a steeper-than-expec
01-23 16:22
Healthcare debate should focus on out-of-pocket costs, not list prices – Novartis CEO
Novartis (NVS) CEO Vas Narasimhan argued that the healthcare debate in the U.S. needs to shift away from list prices and net prices toward a focus on reducing patient out-of-pocket costs. In an interv...
01-23 02:04
